ArticleInfectious diseases and therapy2026
Cost-Effectiveness of Alternative Immunization Strategies to Protect Infants Against Respiratory Syncytial Virus in Germany: A Decision Modeling Study.
Article in Infectious diseases and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionGermany's Standing Committee on Vaccination (STIKO) recommends the use of monoclonal antibody nirsevimab for infants in their first respiratory syncytial virus (RSV) season; however, incorporating RSVpreF maternal vaccination may protect more infants while lowering healthcare costs. We therefore evaluated the cost-effectiveness of a complementary immunization approach comprising maternal RSVpreF vaccination during pregnancy and nirsevimab for infants not yet protected to prevent lower respiratory tract disease due to RSV (RSV-LRTD) among infants in Germany.
methodsClinical and economic outcomes of RSV-LRTD and the expected impact of interventions were modeled from birth to age < 1 year. Model inputs were based on German data as available. Intervention strategies included no intervention, nirsevimab alone (N-all; uptake 70%), and the complementary immunization approach (MV + N). MV + N comprised seasonally administered maternal vaccination (MV; uptake 50%) with nirsevimab (N; uptake 70%) for unprotected infants (MV + N). Nirsevimab was administered seasonally with catch-up for infants born outside the RSV season. Analyses were conducted from the societal perspective and discounted 3% annually.
resultsWithout immunization, 70,041 cases of RSV-LRTD (hospital: 23,273, ambulatory: 46,768) and 22 deaths were projected; total RSV-attributable medical care costs were 118.6 million (M) €. With N-all, there were 39,247 cases (hospital 12,953; ambulatory 26,294) and 13 deaths; total associated costs were 311.5M € (intervention 237.2M €; medical care 66.0M €; indirect 8.4M €). Compared to N-all, MV + N prevented an additional 666 cases and 1 death, with a difference in total costs of - 17.8M € (intervention - 12.7M €; medical care - 4.7M €; indirect - 0.4M €). With 31 QALYs gained, MV + N was dominant versus N-All.
conclusionA complementary strategy with maternal RSVpreF vaccination and nirsevimab immunization for otherwise unprotected and preterm infants in Germany would provide a greater benefit compared to nirsevimab alone, protecting substantially more infants at lower total costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.